Trial Profile
Evaluation of the Analgesic Effects of Prolonged-release Oxycodone and of Levodopa, Versus Placebo, on Central Neuropathic Pain in Parkinson's Disease: OXYDOPA Trial
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 04 Mar 2022
Price :
$35
*
At a glance
- Drugs Oxycodone (Primary) ; Levodopa
- Indications Neuropathic pain
- Focus Therapeutic Use
- Acronyms OXYDOPA
- 28 Feb 2022 Status changed from recruiting to completed.
- 19 Aug 2019 Planned number of patients changed from 75 to 84.
- 19 Aug 2019 Planned End Date changed from 1 Apr 2020 to 1 Sep 2021.